{"id":"https://genegraph.clinicalgenome.org/r/63c0ff76-e749-454f-9db2-513bf2974f05v1.0","type":"EvidenceStrengthAssertion","dc:description":"The human RAD50 gene (hRAD50) is located on chromosome 5q31 and encodes the 153 kDa RAD50 protein. It plays key roles in DNA double strand breaks (DSBs) repairs, which are crucial to safeguarding genome integrity and sustaining tumor suppression.  Biallelic RAD50 mutations are also associated with Nijmegen breakage syndrome-like disorder (autosomal recessive). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we only focus on autosomal dominant hereditary ovarian cancer (refute the association with ovarian cancer) in this curation. Evidence refuting this gene-disease relationship includes case-control data (0 Point) and experimental data (0 Point). This gene-disease relationship has been studied in at least 2 large case-control studies at the aggregate variant level (PMID: 28888541, 31406321). Both case-control studies did not support the association of ovarian cancer. Several case level studies were also found, in which individuals with ovarian cancer were tested by multigene panels that included RAD50. One pathogenic variant was identified in RAD50 gene out of 360 women with ovarian cancer (PMID: 22006311), while most studies did not identify pathogenic variants in the RAD50 gene (PMID: 29020732, 36531003, 31472684). A study on a mouse homozygous for a hypomorphic RAD50 allele (pLys22Met) resulted in ~20% of mice died with metastatic thymic lymphoma, splenic hyperplasia or myeloid leukemia. However, these mice did not develop ovarian cancer. (0 point, PMID: 12208847). Another study showed tumorigenesis in  RAD50 mutant medaka, but it was not seen in the ovaries (PMID: 37098078). In summary, given the lack of significant association in large case-control studies and a number of ovarian cancer cohort studies not finding an association with RAD50 there is convincing evidence refuting the association between RAD50 and autosomal dominant hereditary ovarian cancer, which significantly outweighs the evidence supporting the association. This gene-disease pair was originally evaluated as disputed by the Breast/Ovarian Cancer GCEP on 10/26/2016. This re-curation was approved as refuted by the ClinGen Hereditary Cancer GCEP on 2/23/2024 (SOP Version 10). ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/63c0ff76-e749-454f-9db2-513bf2974f05","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54","calculatedEvidenceStrength":"NoKnownDiseaseRelationship","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-02-23T18:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-04-11T21:42:26.380Z","role":"Publisher"}],"curationReasonDescription":"Given the lack of significant association in large case-control studies and a number of ovarian cancer cohort studies not finding an association with RAD50 there is convincing evidence refuting the association between RAD50 and autosomal dominant hereditary ovarian cancer, which significantly outweighs the evidence supporting the association. ","curationReasons":["RecurationFrameworkChange","RecurationTiming","RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53f9be05-1668-4d9b-9c16-c2483917f746","type":"EvidenceLine","dc:description":"A 2-base pair deletion in the RAD50 gene (c.1515_1516 del AA, p.I505fs*5) was introduced into medaka using the CRISPR/Cas9 system (also used a 9 base pair deletion that retained some RAD50 function). The mutant fish were analyzed histologically for tumorgenicity and hindbrain quality andÂ swimming behavior. There was tumorigenesis in 8 out 10 of the histologically analyzed fish and a decrease in median survival. Not scored, since no ovarian cancer developed.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/983c18ed-ea68-4198-a580-576f6d91e4d9","type":"Finding","dc:description":"Histology was examined of thyroid ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37098078","rdfs:label":"Medaka model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4aeb0753-005d-4730-8c15-19d7e1647265","type":"EvidenceLine","dc:description":"No ovarian cancer seen in the mouse model","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f9b1f55d-ca8f-4401-904b-fc528892fc9e","type":"Finding","dc:description":"Phenotype seen is mouse is cancer","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12208847","rdfs:label":"RAD50S/S","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24956359-7eef-4460-bddf-c31b688f0fee","type":"EvidenceLine","dc:description":"Sequenced for 360 women with ovarian, fallopian tube, or peritoneal carcinoma. 85 germline loss-of-function mutations were identified in 12 genes (21 multigene panel was used). However, only one patient was identified to have a RAD50 mutation\n","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24956359-7eef-4460-bddf-c31b688f0fee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22006311","allele":{"id":"https://genegraph.clinicalgenome.org/r/d3c54f0c-37a8-4dfc-bc42-2ab85aec26d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005732.4(RAD50):c.2797_2810del (p.Lys933GlnfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695205202"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e26bb55-3966-4059-97d3-7c9e6e10d91b","type":"EvidenceLine","direction":"Contradicts","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e26bb55-3966-4059-97d3-7c9e6e10d91b_cc_evidence_item","type":"Finding","dc:description":"Please note, the number of variants identified from control group was unknown since the data is from ExAC database.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28888541","rdfs:label":"Lilyquist et al case-control","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/acab5a28-01a1-4ada-bc6e-aefe7a649e9c","type":"Cohort","allGenotypedSequenced":6294,"alleleFrequency":0.001906577693040991,"detectionMethod":"Panel including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D genes.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e26bb55-3966-4059-97d3-7c9e6e10d91b_cc_evidence_item"}],"numWithVariant":12,"relatedCondition":{"id":"obo:MONDO_0016248"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/0bf5220d-3693-481f-8fe4-70e6bfa9c100","type":"Cohort","allGenotypedSequenced":7768,"alleleFrequency":0,"detectionMethod":"Controls were from ExAC ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e26bb55-3966-4059-97d3-7c9e6e10d91b_cc_evidence_item"}],"numWithVariant":0},"lowerConfidenceLimit":0.45,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.57,"statisticalSignificanceType":"","statisticalSignificanceValue":0.88,"statisticalSignificanceValueType":"Relative Risk","upperConfidenceLimit":1.53}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/f4b305a2-abae-4850-a94b-ab533e457273","type":"EvidenceLine","direction":"Contradicts","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4b305a2-abae-4850-a94b-ab533e457273_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31406321","rdfs:label":"LaDuca et al. ","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/84d48878-d89d-4262-a489-c09935ab88b4","type":"Cohort","allGenotypedSequenced":155406,"alleleFrequency":0.00211060062031067,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4b305a2-abae-4850-a94b-ab533e457273_cc_evidence_item"}],"numWithVariant":328,"relatedCondition":{"id":"obo:MONDO_0016248"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/ce27cffa-acca-4273-9fa7-05db730742f8","type":"Cohort","allGenotypedSequenced":111109,"alleleFrequency":0.001206022914435374,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4b305a2-abae-4850-a94b-ab533e457273_cc_evidence_item"}],"numWithVariant":134},"lowerConfidenceLimit":0.65,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.56,"statisticalSignificanceType":"","statisticalSignificanceValue":1.17,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":2}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria"}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Refuted","sequence":8157,"specifiedBy":"GeneValidityCriteria10","strengthScore":0,"subject":{"id":"https://genegraph.clinicalgenome.org/r/UJDdd9pH0Aw","type":"GeneValidityProposition","disease":"obo:MONDO_0016248","gene":"hgnc:9816","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ef809b24-cdc2-4d5c-a1ab-5a9c2f35da54-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}